Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
vedolizumab (Genentech)
- Development stage
- Approved
- Lead developer
- Takeda
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Subcutaneous
01
Overview
Vedolizumab (formerly known as LDP-02 and MLN0002) is a humanized monoclonal antibody that specifically targets the alpha4beta7 integrin receptor on leukocytes. By binding to this integrin, vedolizumab inhibits the migration of memory T-lymphocytes into gastrointestinal tissue, thereby reducing inflammation associated with inflammatory bowel diseases (IBD) such as Crohn's disease and ulcerative colitis. The drug was originally developed by LeukoSite (later acquired by Millennium Pharmaceuticals), in collaboration with Genentech, for intravenous and subcutaneous administration in acute IBD. Its mechanism offers gut-selective immunosuppression, aiming to minimize systemic immune effects[1][2][5].
- Brand names
- Entyvio
- Other names
- anti-integrin α4β7anti-human integrin α4β7
02
Targets
α4β7 (Integrin alpha-4 beta-7 heterodimer)
Beyond the preview
Go deeper on vedolizumab (Genentech).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on vedolizumab (Genentech).